Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma

Published:2020-02 Issue:2 Volume:72 Page:307-319
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Cheng Ann-Lii,Hsu Chiun,Chan Stephen L.,Choo Su-Pin,Kudo Masatoshi

Funder

Centers of Genomic and Precision Medicine

National Taiwan University

Ministry of Education, Taiwan

Publisher

Elsevier BV

Subject

Hepatology

Reference156 articles.

1. Targeting T cell co-receptors for cancer therapy;Callahan;Immunity,2016

2. Development of immuno-oncology drugs – from CTLA4 to PD1 to the next generations;Hoos;Nat Rev Drug Discov,2016

3. Comprehensive analysis of the clinical immuno-oncology landscape;Tang;Ann Oncol,2018

4. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma;Motzer;N Engl J Med,2018

5. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer;Overman;J Clin Oncol,2018

Cited by 362 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapeutic strategies in hepatopancreatobiliary cancers;Principles of Immunotherapy Breast and Gastrointestinal Cancers;2025

2. Prediction of drug targets related to HCC metastasis from the perspective of programmed cell death based on transformer;Future Generation Computer Systems;2024-11

3. Recent advancements in the small-molecule drugs for hepatocellular carcinoma (HCC): Structure-activity relationships, pharmacological activities, and the clinical trials;Biomedicine & Pharmacotherapy;2024-10

4. Unraveling the role of ADAMs in clinical heterogeneity and the immune microenvironment of hepatocellular carcinoma: insights from single-cell, spatial transcriptomics, and bulk RNA sequencing;Frontiers in Immunology;2024-09-13

5. Targeting PRMT3 impairs methylation and oligomerization of HSP60 to boost anti-tumor immunity by activating cGAS/STING signaling;Nature Communications;2024-09-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3